COMPLEMENT PROPHYLACTIQUE A BASE DE 17A-ACYLOXY-6 METHYLPREGNA-4,6-DIENE-3,20-DIONE

The use of a 17 alpha-acyloxy-6-methyl pregna-4,6-dien-3,20 dione (I) in which the acyl group has up to 10C atoms, as a therapeutic agent for oral or parenteral admin. to patients or animals who have undergone mastectomy following breast cancer, is new. The admin. is continued until there is no furt...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	MARTIN O. GREANEY ET MERRITT R. CALLANTINE
Format:	Patent
Sprache:	fre
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS STEROIDS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	MARTIN O. GREANEY ET MERRITT R. CALLANTINE
description	The use of a 17 alpha-acyloxy-6-methyl pregna-4,6-dien-3,20 dione (I) in which the acyl group has up to 10C atoms, as a therapeutic agent for oral or parenteral admin. to patients or animals who have undergone mastectomy following breast cancer, is new. The admin. is continued until there is no further risk of matastatic transmission or recurrence of the cancer. Better activity than known therapeutic agents, and absence of toxicity. (I) is preferably given as soon after the mastectomy as possible, and it is continued for 2-5 years. The daily dosage is 40-800 mg preferably 160-320 mg, given in 2-8 doses, pref. 4. (I) may be given with other active components, such as digitalin, insulin, non-steroidal anti-inflammatories, and analgesics.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_FR2534476B1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>FR2534476B1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_FR2534476B13</originalsourceid><addsrcrecordid>eNrjZAh29vcN8HH1dfULUQgI8g_wiPRxdA7xDAx1VXBUcHIMdlVwcVUwNHfUdXSO9PGPiNQ1U_B1DQGqCghydfdz1DXRMdN18XT1c9U11jEyADL9_Vx5GFjTEnOKU3mhNDeDgptriLOHbmpBfnxqcUFicmpeakm8W5CRqbGJibmZk6ExEUoAQmUujA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>COMPLEMENT PROPHYLACTIQUE A BASE DE 17A-ACYLOXY-6 METHYLPREGNA-4,6-DIENE-3,20-DIONE</title><source>esp@cenet</source><creator>MARTIN O. GREANEY ET MERRITT R. CALLANTINE</creator><creatorcontrib>MARTIN O. GREANEY ET MERRITT R. CALLANTINE</creatorcontrib><description>The use of a 17 alpha-acyloxy-6-methyl pregna-4,6-dien-3,20 dione (I) in which the acyl group has up to 10C atoms, as a therapeutic agent for oral or parenteral admin. to patients or animals who have undergone mastectomy following breast cancer, is new. The admin. is continued until there is no further risk of matastatic transmission or recurrence of the cancer. Better activity than known therapeutic agents, and absence of toxicity. (I) is preferably given as soon after the mastectomy as possible, and it is continued for 2-5 years. The daily dosage is 40-800 mg preferably 160-320 mg, given in 2-8 doses, pref. 4. (I) may be given with other active components, such as digitalin, insulin, non-steroidal anti-inflammatories, and analgesics.</description><edition>4</edition><language>fre</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; STEROIDS</subject><creationdate>1987</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19870731&DB=EPODOC&CC=FR&NR=2534476B1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,777,882,25545,76296</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19870731&DB=EPODOC&CC=FR&NR=2534476B1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>MARTIN O. GREANEY ET MERRITT R. CALLANTINE</creatorcontrib><title>COMPLEMENT PROPHYLACTIQUE A BASE DE 17A-ACYLOXY-6 METHYLPREGNA-4,6-DIENE-3,20-DIONE</title><description>The use of a 17 alpha-acyloxy-6-methyl pregna-4,6-dien-3,20 dione (I) in which the acyl group has up to 10C atoms, as a therapeutic agent for oral or parenteral admin. to patients or animals who have undergone mastectomy following breast cancer, is new. The admin. is continued until there is no further risk of matastatic transmission or recurrence of the cancer. Better activity than known therapeutic agents, and absence of toxicity. (I) is preferably given as soon after the mastectomy as possible, and it is continued for 2-5 years. The daily dosage is 40-800 mg preferably 160-320 mg, given in 2-8 doses, pref. 4. (I) may be given with other active components, such as digitalin, insulin, non-steroidal anti-inflammatories, and analgesics.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>STEROIDS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>1987</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZAh29vcN8HH1dfULUQgI8g_wiPRxdA7xDAx1VXBUcHIMdlVwcVUwNHfUdXSO9PGPiNQ1U_B1DQGqCghydfdz1DXRMdN18XT1c9U11jEyADL9_Vx5GFjTEnOKU3mhNDeDgptriLOHbmpBfnxqcUFicmpeakm8W5CRqbGJibmZk6ExEUoAQmUujA</recordid><startdate>19870731</startdate><enddate>19870731</enddate><creator>MARTIN O. GREANEY ET MERRITT R. CALLANTINE</creator><scope>EVB</scope></search><sort><creationdate>19870731</creationdate><title>COMPLEMENT PROPHYLACTIQUE A BASE DE 17A-ACYLOXY-6 METHYLPREGNA-4,6-DIENE-3,20-DIONE</title><author>MARTIN O. GREANEY ET MERRITT R. CALLANTINE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_FR2534476B13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>fre</language><creationdate>1987</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>STEROIDS</topic><toplevel>online_resources</toplevel><creatorcontrib>MARTIN O. GREANEY ET MERRITT R. CALLANTINE</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>MARTIN O. GREANEY ET MERRITT R. CALLANTINE</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>COMPLEMENT PROPHYLACTIQUE A BASE DE 17A-ACYLOXY-6 METHYLPREGNA-4,6-DIENE-3,20-DIONE</title><date>1987-07-31</date><risdate>1987</risdate><abstract>The use of a 17 alpha-acyloxy-6-methyl pregna-4,6-dien-3,20 dione (I) in which the acyl group has up to 10C atoms, as a therapeutic agent for oral or parenteral admin. to patients or animals who have undergone mastectomy following breast cancer, is new. The admin. is continued until there is no further risk of matastatic transmission or recurrence of the cancer. Better activity than known therapeutic agents, and absence of toxicity. (I) is preferably given as soon after the mastectomy as possible, and it is continued for 2-5 years. The daily dosage is 40-800 mg preferably 160-320 mg, given in 2-8 doses, pref. 4. (I) may be given with other active components, such as digitalin, insulin, non-steroidal anti-inflammatories, and analgesics.</abstract><edition>4</edition><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	fre
recordid	cdi_epo_espacenet_FR2534476B1
source	esp@cenet
subjects	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS STEROIDS
title	COMPLEMENT PROPHYLACTIQUE A BASE DE 17A-ACYLOXY-6 METHYLPREGNA-4,6-DIENE-3,20-DIONE
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T01%3A12%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=MARTIN%20O.%20GREANEY%20ET%20MERRITT%20R.%20CALLANTINE&rft.date=1987-07-31&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EFR2534476B1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true